{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:49:27Z","timestamp":1774950567827,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015825","name":"Korea University Anam Hospital","doi-asserted-by":"publisher","award":["2023AN0182"],"award-info":[{"award-number":["2023AN0182"]}],"id":[{"id":"10.13039\/501100015825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinthera.2025.08.012","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T04:01:03Z","timestamp":1757822463000},"page":"1028-1036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial"],"prefix":"10.1016","volume":"47","author":[{"given":"Soon Jun","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Bae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Youn","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goo-Yeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok-Kyu","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Pil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Eun","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kye Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeonju","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moo-Yong","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kye Tack","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Won","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Yeub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Joon","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Haeng","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang-Won","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Hwa","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Don","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong Chol","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Yong","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8260-2958","authenticated-orcid":false,"given":"Jong-Won","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.08.012_bib0001","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11883-023-01132-z","article-title":"Hypertension and dyslipidemia: the two partners in endothelium-related crime","volume":"25","author":"Dabrowska","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0002","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/2230-8210.93742","article-title":"LIPITENSION: interplay between dyslipidemia and hypertension","volume":"16","author":"Dalal","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0003","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0004","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003053","article-title":"Dyslipidemia and the risk of developing hypertension in a working-age male population","volume":"5","author":"Otsuka","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40885-023-00243-8","article-title":"Korea hypertension fact sheet 2022: analysis of nationwide population-based data with a special focus on hypertension in the elderly","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0006","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3349\/ymj.2017.58.2.326","article-title":"Management status of cardiovascular disease risk factors for dyslipidemia among Korean adults","volume":"58","author":"Lee","year":"2017","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0007","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0008","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/11593840-000000000-00000","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of Fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects","volume":"11","author":"Chi","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0009","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.clinthera.2012.04.021","article-title":"Efficacy and tolerability of once-daily oral Fimasartan 20 to 240 mg\/d in Korean Patients with hypertension: findings from Two phase II, randomized, double-blind, placebo-controlled studies","volume":"34","author":"Lee","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0010","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.2147\/DDDT.S82098","article-title":"Efficacy of Fimasartan\/hydrochlorothiazide combination in hypertensive patients inadequately controlled by Fimasartan monotherapy","volume":"9","author":"Rhee","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0011","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.clinthera.2013.06.021","article-title":"Ambulatory blood pressure response to once-daily Fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension","volume":"35","author":"Lee","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0012","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.clinthera.2016.04.005","article-title":"A randomized, double-blind, candesartan-controlled, parallel group comparison clinical trial to evaluate the antihypertensive efficacy and safety of Fimasartan in patients with mild to moderate essential hypertension","volume":"38","author":"Lee","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0013","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/jch.14536","article-title":"Comparative efficacy and safety of Fimasartan in patients with hypertension: a network meta-analysis of randomized controlled trials","volume":"24","author":"Seo","year":"2022","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0014","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.clinthera.2022.08.013","article-title":"Efficacy and tolerability of ezetimibe\/atorvastatin fixed-dose combination versus atorvastatin monotherapy in hypercholesterolemia: a phase III, randomized, active-controlled study in Chinese patients","volume":"44","author":"Qian","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0015","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.clinthera.2017.07.038","article-title":"Comparison of pharmacokinetics and safety of a fixed-dose combination of rosuvastatin and ezetimibe versus separate tablets in healthy subjects","volume":"39","author":"Min","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0016","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40360-016-0112-7","article-title":"The efficacy and safety of co-administration of Fimasartan and rosuvastatin to patients with hypertension and dyslipidemia","volume":"18","author":"Rhee","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0017","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40885-022-00223-4","volume":"28","author":"Jeon","year":"2022","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0018","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.3390\/jcm12062377","article-title":"Efficacy and safety of coadministered ezetimibe-rosuvastatin plus telmisartan in south Korean patients with dyslipidemia and hypertension: a multicenter, randomized, double-blind, active-controlled, phase III trial","volume":"12","author":"Song","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0019","doi-asserted-by":"crossref","first-page":"815","DOI":"10.5603\/CJ.a2020.0167","article-title":"Effect of FIXed-dose combination of ARb and statin on adherence and risk factor control: the randomized FIXAR study","volume":"29","author":"Chung","year":"2022","journal-title":"Cardiol J"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40885-023-00234-9","article-title":"The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221138284","article-title":"A phase 3 randomized controlled trial to evaluate efficacy and safety of new-formulation Zenon (rosuvastatin\/ezetimibe fixed-dose combination) in primary hypercholesterolemia inadequately controlled by statins","volume":"27","author":"Catapano","year":"2022","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0024","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0025","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11906-006-0028-5","article-title":"Management of hypertension and dyslipidemia","volume":"8","author":"Ferdinand","year":"2006","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0026","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clinthera.2019.02.013","article-title":"Efficacy and tolerability of telmisartan\/amlodipine and rosuvastatin coadministration in hypertensive patients with hyperlipidemia: a phase III, multicenter, randomized, double-blind study","volume":"41","author":"Kim","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0027","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jch.14778","article-title":"Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: a randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial","volume":"26","author":"Lee","year":"2024","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0028","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.clinthera.2020.03.019","article-title":"Effectiveness of Fimasartan and rosuvastatin combination treatment in hypertensive patients with dyslipidemia","volume":"42","author":"Lee","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0029","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1081\/JDI-56610","article-title":"Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients","volume":"27","author":"Kanbay","year":"2005","journal-title":"Ren Fail"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0030","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1161\/01.CIR.0000143085.86697.13","article-title":"Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients","volume":"110","author":"Koh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0031","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/HJH.0000000000002276","article-title":"Statin therapy is associated with better ambulatory blood pressure control: a propensity score analysis","volume":"38","author":"Spannella","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0032","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/jch.12081","article-title":"Antihypertensive effects of statins: a meta-analysis of prospective controlled studies","volume":"15","author":"Briasoulis","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0033","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/01.HYP.0000259737.43916.42","article-title":"Do statins reduce blood pressure?: A meta-analysis of randomized, controlled trials","volume":"49","author":"Strazzullo","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0034","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0035","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s12325-020-01592-8","article-title":"Pharmacokinetic interaction between telmisartan and rosuvastatin\/ezetimibe after multiple oral administration in healthy subjects","volume":"38","author":"Kim","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0036","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cpdd.926","article-title":"Pharmacokinetic interaction among ezetimibe, rosuvastatin, and telmisartan","volume":"10","author":"Huh","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0037","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s00392-023-02257-6","article-title":"Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany","volume":"113","author":"Koenig","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0038","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/jhh.2008.114","article-title":"Single-pill amlodipine\/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)","volume":"23","author":"Erdine","year":"2009","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.clinthera.2025.08.012_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.836970","article-title":"Pharmacokinetics and genetic factors of atorvastatin in healthy Korean subjects","volume":"13","author":"Kim","year":"2022","journal-title":"Front Genet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:55:28Z","timestamp":1774947328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0149291825002942"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.08.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}